/news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997092.cms01
Japanese drugmaker Daiichi Sankyo is close to exiting India, ending a bitter 7-year run that saw it face regulatory challenges in several countries because of its ownership of Ranbaxy Laboratories, which it had bought from the Delhi-based Singh family in 2008 - Photogallery
Japanese drugmaker Daiichi Sankyo is close to exiting India, ending a bitter 7-year run that saw it face regulatory challenges in several countries because of its ownership of Ranbaxy Laboratories, which it had bought from the Delhi-based Singh family in 2008. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
Japanese drugmaker Daiichi Sankyo is close to exiting India, ending a bitter 7-year run that saw it face regulatory challenges in several countries because of its ownership of Ranbaxy Laboratories, which it had bought from the Delhi-based Singh family in 2008. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997087.cms02
Daiichi is planning to sell the nearly 9% stake it currently holds in Indian pharma major Sun Pharmaceuticals, worth about Rs 22,300 crore (about $3 - Photogallery
Daiichi is planning to sell the nearly 9% stake it currently holds in Indian pharma major Sun Pharmaceuticals, worth about Rs 22,300 crore (about $3.6 billion) at Monday's close of market, through block deals on Tuesday. If completed successfully, this will be the largest block deal in Indian history. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
Daiichi is planning to sell the nearly 9% stake it currently holds in Indian pharma major Sun Pharmaceuticals, worth about Rs 22,300 crore (about $3.6 billion) at Monday's close of market, through block deals on Tuesday. If completed successfully, this will be the largest block deal in Indian history. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997086.cms03
Earlier this month, Sun Pharma announced the close of its buyout of Ranbaxy in a stock-swap deal which resulted into Daiichi holding 8 - Photogallery
Earlier this month, Sun Pharma announced the close of its buyout of Ranbaxy in a stock-swap deal which resulted into Daiichi holding 8.9% in India's largest drugmaker by sales. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
Earlier this month, Sun Pharma announced the close of its buyout of Ranbaxy in a stock-swap deal which resulted into Daiichi holding 8.9% in India's largest drugmaker by sales. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997084.cms04
The closure of the deal will mean a cash loss of at least $600 million for Daiichi over seven years - Photogallery
The closure of the deal will mean a cash loss of at least $600 million for Daiichi over seven years. In 2008, Daiichi bought over the promoters' stake in Ranbaxy for $4.2 billion while now it is set to get about $3.6 billion by selling its stake in Sun Pharma. The closure of the deal will mean a cash loss of at least $600 million for Daiichi over seven years. In 2008, Daiichi bought over the promoters' stake in Ranbaxy for $4.2 billion while now it is set to get about $3.6 billion by selling its stake in Sun Pharma. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997083.cms05
According to the term sheet for the deal, Sun Pharma shares are being offered in a band of Rs 930-1,040, a discount of as much as 11% at the lower end of the price band to the stock's Monday close at Rs 1,044 - Photogallery
According to the term sheet for the deal, Sun Pharma shares are being offered in a band of Rs 930-1,040, a discount of as much as 11% at the lower end of the price band to the stock's Monday close at Rs 1,044. The book for the block deal is being offered through an accelerated book building process. ()See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
According to the term sheet for the deal, Sun Pharma shares are being offered in a band of Rs 930-1,040, a discount of as much as 11% at the lower end of the price band to the stock's Monday close at Rs 1,044. The book for the block deal is being offered through an accelerated book building process. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997082.cms06
However, the Japanese firm said that its existing business partnership with Sun Pharma will continue - Photogallery
However, the Japanese firm said that its existing business partnership with Sun Pharma will continue. However, the Japanese firm said that its existing business partnership with Sun Pharma will continue. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997079.cms07
According to a Reuters report, in an exchange filing in Japan, Daiichi said its board had approved the sale of all or part of the Sun Pharma stake, although it did not give any reason for its decision to exit the Indian drug major - Photogallery
According to a Reuters report, in an exchange filing in Japan, Daiichi said its board had approved the sale of all or part of the Sun Pharma stake, although it did not give any reason for its decision to exit the Indian drug major. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
According to a Reuters report, in an exchange filing in Japan, Daiichi said its board had approved the sale of all or part of the Sun Pharma stake, although it did not give any reason for its decision to exit the Indian drug major. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997081.cms08
There were market rumours that Sun Pharma's promoters were buying half the block being offered by the Japanese firm - Photogallery
There were market rumours that Sun Pharma's promoters were buying half the block being offered by the Japanese firm. However, a spokesman for Sun Pharma said neither the company nor its promoters are buying any share in the block deal being offered by Daiichi. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
There were market rumours that Sun Pharma's promoters were buying half the block being offered by the Japanese firm. However, a spokesman for Sun Pharma said neither the company nor its promoters are buying any share in the block deal being offered by Daiichi. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997078.cms09
According to a note by a brokerage house, institutional investors who are being offered the shares should subscribe to the offer because of at least three reasons - Photogallery
According to a note by a brokerage house, institutional investors who are being offered the shares should subscribe to the offer because of at least three reasons. One, the stocks are being offered at a significant discount to the market price. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
According to a note by a brokerage house, institutional investors who are being offered the shares should subscribe to the offer because of at least three reasons. One, the stocks are being offered at a significant discount to the market price. /news/business/sun-pharma-exit-may-net-daiichi-3-6bn/eventshow/46997077.cms10
Secondly, the expected synergy from consolidation of Ranbaxy into Sun Pharma, at the current price, appears to be under appreciated - Photogallery
Secondly, the expected synergy from consolidation of Ranbaxy into Sun Pharma, at the current price, appears to be under appreciated. And lastly, Sun Pharma's track record of turning around stressed assets is also a positive for investors to buy the stock. See more of :
Sun Pharma exit may net Daiichi $3.6bnSun Pharma exit may net Daiichi $3.6bn
Secondly, the expected synergy from consolidation of Ranbaxy into Sun Pharma, at the current price, appears to be under appreciated. And lastly, Sun Pharma's track record of turning around stressed assets is also a positive for investors to buy the stock. 
